Innate Pharma announces its participation in upcoming investor conference
Number of shares and voting rights of Innate Pharma as of July 10, 2024
Number of shares and voting rights of Innate Pharma as of June 10, 2024
Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in mycosis fungoides
Innate Pharma announces its participation in upcoming investor conferences
Innate Pharma highlights abstracts selected for ASCO 2024 Annual Meeting
Outcome of Innate Pharma’s 2024 Annual General Meeting
Clarification regarding SAR443579 Designation
Innate Pharma highlights abstracts selected for EHA 2024 congress
